Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
26.84
+0.54 (2.05%)
At close: May 12, 2026, 4:00 PM EDT
26.89
+0.05 (0.19%)
After-hours: May 12, 2026, 6:26 PM EDT
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company’s products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.
| Name | Position |
|---|---|
| Dr. Emil D. Kakkis M.D., Ph.D. | Founder, President, CEO & Director |
| Dr. Eric Crombez M.D. | Chief Medical Officer & Executive VP |
| Mr. Dennis Karl Huang | Chief Technical Operations Officer and Executive VP of Gene Therapy Operations |
| Mr. Erik Harris M.B.A. | Executive VP & Chief Commercial Officer |
| Mr. Ernie W. Meyer | Chief Human Resources Officer & Executive VP |
| Mr. Howard Horn | Executive VP of Corporate Strategy & CFO |
| Mr. John Richard Pinion II | Chief Quality Operations Officer & Executive VP of Translational Sciences |
| Mr. Theodore A. Huizenga | Senior VP, Corporate Controller & Principal Accounting Officer |
| Mr. Vimal Srivastava | Senior Vice President of Business Development & Alliance Management |
| Ms. Karah Herdman Parschauer J.D. | Chief Legal Officer & Executive VP of Corporate Affairs |
| Date | Type | Document |
|---|---|---|
| 2026-05-06 | 10-Q | rare-20260331.htm |
| 2026-05-05 | 8-K | rare-20260505.htm |
| 2026-04-02 | 8-K | rare-20260402.htm |
| 2026-03-30 | 8-K | rare-20260330.htm |
| 2026-03-27 | DEFA14A | rare015368-defa14a.htm |
| 2026-03-12 | 8-K | rare-20260312.htm |
| 2026-02-23 | 8-K | rare-20260223.htm |
| 2026-02-18 | 10-K | rare-20251231.htm |
| 2026-02-12 | 8-K | rare-20260212.htm |
| 2026-02-03 | 8-K | rare-20260203.htm |